Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2198959rdf:typepubmed:Citationlld:pubmed
pubmed-article:2198959lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:2198959lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2198959lifeskim:mentionsumls-concept:C2323499lld:lifeskim
pubmed-article:2198959lifeskim:mentionsumls-concept:C0080096lld:lifeskim
pubmed-article:2198959pubmed:issue3lld:pubmed
pubmed-article:2198959pubmed:dateCreated1990-9-11lld:pubmed
pubmed-article:2198959pubmed:abstractTextA novel human cell line, KMT-2, from umbilical cord blood cells was established based on the selection of cultures in the presence of recombinant human interleukin-3 (IL-3) and the sorting of cells with anti-My 10 antibody. Morphologic and cytochemical studies (peroxidase negative, Sudan-black negative, chloroacetate esterase negative, PAS positive, nonspecific esterase positive) and phenotyping (HLA-DR, My7 = CD13, My9 = CD33, My10 = CD34, MCS-2, LeuM1 positive, glycophorin A negative, and P2 negative) suggest that the KMT-2 cells are myelomonocytic cells, probably of immature progenitor origin. Besides IL-3, granulocyte-macrophage colony-stimulating factor supported the growth of the KMT-2 cells, but IL-1 alpha, IL-2, IL-4, IL-5, and erythropoietin did not. IL-6 showed only slight activity. Binding studies with 125I-labeled recombinant human (rh) IL-3 indicated that IL-3 bound to a single class of high affinity receptors (approximately 4,000 receptors/cell) on KMT-2 cells with a kd of approximately 200 pmol/L. The chemical cross-linking assay demonstrated that radiolabeled hIL-3 bound three molecules with molecular masses of 170, 130, and 70 Kd. Present data suggest that the newly established human cell line will be a valuable tool for the biologic assay of hIL-3, and a model for biochemical studies of IL-3 receptors.lld:pubmed
pubmed-article:2198959pubmed:languageenglld:pubmed
pubmed-article:2198959pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2198959pubmed:citationSubsetAIMlld:pubmed
pubmed-article:2198959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2198959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2198959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2198959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2198959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2198959pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2198959pubmed:statusMEDLINElld:pubmed
pubmed-article:2198959pubmed:monthAuglld:pubmed
pubmed-article:2198959pubmed:issn0006-4971lld:pubmed
pubmed-article:2198959pubmed:authorpubmed-author:OhtaYYlld:pubmed
pubmed-article:2198959pubmed:authorpubmed-author:TanakaHHlld:pubmed
pubmed-article:2198959pubmed:authorpubmed-author:TamuraSSlld:pubmed
pubmed-article:2198959pubmed:authorpubmed-author:SugawaraMMlld:pubmed
pubmed-article:2198959pubmed:authorpubmed-author:SudaTTlld:pubmed
pubmed-article:2198959pubmed:authorpubmed-author:MiyamotoCClld:pubmed
pubmed-article:2198959pubmed:authorpubmed-author:NihiraSSlld:pubmed
pubmed-article:2198959pubmed:authorpubmed-author:TezukaEElld:pubmed
pubmed-article:2198959pubmed:issnTypePrintlld:pubmed
pubmed-article:2198959pubmed:day1lld:pubmed
pubmed-article:2198959pubmed:volume76lld:pubmed
pubmed-article:2198959pubmed:ownerNLMlld:pubmed
pubmed-article:2198959pubmed:authorsCompleteYlld:pubmed
pubmed-article:2198959pubmed:pagination501-7lld:pubmed
pubmed-article:2198959pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:meshHeadingpubmed-meshheading:2198959-...lld:pubmed
pubmed-article:2198959pubmed:year1990lld:pubmed
pubmed-article:2198959pubmed:articleTitleA new hematopoietic cell line, KMT-2, having human interleukin-3 receptors.lld:pubmed
pubmed-article:2198959pubmed:affiliationDepartment of Oncology, Nippon Roche Research Center, Kamakura City, Japan.lld:pubmed
pubmed-article:2198959pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2198959lld:pubmed